Clinical Trial Update: Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC [Phase 2]

View source ↗

Summary

Phase 2 trial investigating tolerance and efficacy of pembrolizumab or cetuximab with radiotherapy in locally advanced head and neck squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Cetuximab (cetuximab)
• Pembrolizumab (pembrolizumab)
• Radiotherapy

Snippet

Sponsor: Groupe Oncologie Radiotherapie Tete et Cou | Conditions: Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Status: COMPLETED